How does this company make money?
The company earns a commission each time a pharmaceutical merchant completes a sale on Tmall. It charges a transaction fee when a prescription reimbursement is processed through Alipay. Businesses using DingTalk for digital health services pay a subscription fee. The company also sells pharmaceuticals directly through its own channels and keeps the margin on those sales.
What makes this company hard to replace?
A patient's prescription history is stored inside Alibaba's ecosystem and would need to be migrated to move to another platform. Their medical insurance reimbursement is processed through Alipay, and replicating that connection elsewhere is not straightforward. Merchants on Tmall have built their pharmaceutical compliance systems specifically around Tmall's marketplace requirements, making it costly and disruptive to rebuild those systems for a different platform.
What limits this company?
Every prescription must be individually approved by a licensed pharmacist — Chinese law does not allow this step to be automated or done in batches. Orders arriving through Tmall and Alipay can multiply almost instantly at almost no extra cost, but pharmacist approvals can only grow as fast as qualified pharmacists can be hired and licensed across multiple provinces. That hiring and licensing process is the ceiling, not the technology.
What does this company depend on?
The company cannot operate without five things: operating licences issued by China's National Medical Products Administration, the Cainiao logistics network for warehousing and dispatch, consumer traffic from Tmall and Taobao, a licensed pharmacist workforce spread across multiple provinces, and the integration with China's national medical insurance reimbursement system.
Who depends on this company?
Tmall and Taobao merchants selling health products rely on this company to handle pharmaceutical fulfilment and regulatory compliance — without it, they could not legally complete those sales. Ele.me users would lose the ability to get prescriptions delivered alongside food orders. Chinese consumers who pay for healthcare through Alipay would lose the ability to process prescription reimbursements in one seamless step.
How does this company scale?
Routing more orders through the Alibaba platform costs almost nothing extra — the software connections to Tmall, Alipay, and Ele.me do not get meaningfully more expensive as volume grows. What does not scale cheaply is pharmacist verification: every additional prescription needs another pharmacist hour, and hiring and licensing pharmacists across provinces takes time and money that grows in step with order volume.
What external forces can significantly affect this company?
China's internet healthcare rules are tightening around data localisation and patient privacy, which could require changes to how prescription and insurance data is stored and shared. The country's ageing population means demand for chronic-disease prescriptions is growing faster than pharmacists are being trained, squeezing the same bottleneck from the demand side. U.S.-China technology restrictions could limit access to international medical device suppliers.
Where is this company structurally vulnerable?
If Chinese regulators restricted or restructured Alipay's authorisation to process medical insurance payments, the reimbursement token would stop being created at the point of purchase. Orders would still arrive through Tmall and Alipay, but they would reach the pharmacist queue without pre-cleared insurance credentials. Without that pre-attached bundle, the platform becomes an ordinary pharmacy competing on pharmacist headcount alone.
CompanyGraph